Bristol Myers Squibb (BMS) is a US-based pharmaceutical company that is building a Chimeric Antigen Receptor T-cell (CAR-T) therapy manufacturing facility in Leiden, Netherlands. The facility will develop and manufacture CAR T-cell therapy for patients with blood cancers, such as leukemia. BMS aims to expand its global network and bring cell therapy closer to European patients through this facility.

MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. 

A privately-held company based in Chicago, MAIA is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials.

MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds.  MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. 

MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.

MAIA Biotechnology, Inc.

On July 28, 2022, we launched our IPO and MAIA was listed on the New York Stock Exchange (NYSE American) in a very challenging environment.

Globally, the number of IPOs in 2022 across all sectors paled in comparison to the year prior, as aggressive interest rate hikes by central banks to curb inflation put an end to the era of cheap money. In the biotech sector, MAIA was one of the only 47 IPOs last year as compared to 152 in 2021.

Join us as we celebrate this important milestone and relive the moment when MAIA rang the opening bell at NYSE!

 #investing #chicago #killcancer #cancer #biotech #telomere #IPO

Time flies! It's been one year since MAIA announced the first patient dosed in THIO-101 clinical trial. The patient continues to be alive and has been free of disease progression for 10.2 months since concluding treatment with THIO and an immune checkpoint inhibitor, without any additional treatment.

https://lnkd.in/eAxiS-Kn

#cancer #biotech #telomere #investing #chicago #killcancer

Noble Capital Markets has updated analysis on MAIA to include the latest releases regarding survival of the first patients dosed with THIO; and they have reiterated a $14 price target in a challenging environment for biotechs. Full report available: https://lnkd.in/ebfUkCqZ

#cancer #biotech #telomere #investing #chicago #killcancer

Of the first 11 patients enrolled in THIO-101 to complete at least 1 post baseline response assessment, 82% met the primary endpoint of disease control (defined as a Complete Response, Partial Response, or Stable Disease). In similar pre-treated patients, the disease control rate is typically in the 25-35% range. 

https://lnkd.in/efzSqt3P

#cancer #biotech #telomere #investing #chicago #killcancer

The first two patients dosed with THIO continue to be alive, 12.2 and 11.5 months from treatment initiation. They have remained free of disease progression for 10.2 and 8.5 months, respectively, without requiring any additional therapy. In real-world scenarios, patients with advanced NSCLC who failed two or more therapies have an expected survival of only 3 to 4 months. Read the full release: https://lnkd.in/eqXsfyp7

Our Phase 2 clinical trial for THIO-101, evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC), has enrolled 29 patients to date, the midpoint to our planned 57 enrolled patients in the first step of Part B of THIO-101. Read the full release: https://lnkd.in/ecG2T-DE

#cancer #biotech #telomere #investing #chicago #killcancer

MAIA has patented a new molecular entity candidate, MAIA-2021-029, for further advancement into preclinical and other studies.

This is the newest addition to MAIA’s Telomere-Targeting Molecule Program, which includes THIO, the lead therapeutic candidate currently being evaluated in a Phase 2 clinical trial, and in-house developed compounds MAIA-2021-020 and MAIA-2022-012, patented in 2022. 

Read the full release here:
https://lnkd.in/g3zfUV_Y

#biotech #telomere #investing #cancer #biotechnology

On June 2nd, MAIA presented at the 9th Annual Immuno-Oncology Innovation Forum hosted by Sachs Associates in Chicago.
 
Dr. Vitoc and Dr. Obrocea presented THIO and MAIA's Phase II clinical trials to an audience of leaders from cancer research institutes, patient advocacy groups, pharma, biotech, and Wall Street. Learn more about the event at:
https://lnkd.in/gp3efVQR
 
#IOIF2023 #oncology #ImmunoOncology #biotech #telomere

Why is everyone so excited about our trial in patients with lung cancer? Hear from Vlad about the excellent pre-clinical results that led THIO to clinical trials!
 
Watch the entire presentation on YouTube: https://lnkd.in/eraSJxHd

Join our Newsletter to receive the latest and greatest from MAIA: http://eepurl.com/iejhHD
 
#cancer #killcancer #biotech #telomere #investing #chicago

Following the excellent safety and preliminary survival data for our THIO-101 clinical trial and Q1 financial reports, Noble Capital Markets and Diamond Equity have reiterated their stock price targets for MAIA - a testament to this unique investment opportunity.
https://lnkd.in/eQV8SRmn

#cancer #killcancer #biotech #telomere #investing

COM:PHARMACEUTICAL-TECHNOLOGY

Bristol Myers Squibb

Analysis Not Available